Kdm1a inhibitors for the treatment of disease
AssigneeImago Biosciences, Inc.
InventorsHugh Y. Rienhoff, Jr., Cassandra Celatka, Amy E. Tapper, Nivedita Namdev, Michael Clare
Life of this patent
Estimating the term…
Abstract
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
Claims76
A compound of Formula I:
- or a salt or tautomer thereof, wherein:
- L1 is chosen from a bond and —(CH2)k—;
- L2 is chosen from —C(O)NH—, —NHC(O)—, and —C(O)—;
- R1 is chosen from phenyl, 5-membered monocyclic heteroaryl, and 10-membered bicyclic heteroaryl, either of which is substituted with one R5a and one or more R5b;
- R2 is chosen from cyclohexyl, azetidinyl, pyrrolidinyl, and piperidinyl, any of which is optionally substituted with one or more R6;
- k is chosen from 1, 2, and 3;
- R4 is phenyl substituted with one R7a and one or more R7b;
- R5a is chosen from CH3, CH2CH3, OCH3, 5- to 6-membered heterocycloalkyl, and 5-membered monocyclic heteroaryl, and 10-membered bicyclic heteroaryl, wherein the heterocycloalkyl and heteroaryl are optionally substituted by one or more R9;
- each R5b is independently chosen from H, halo, and OCH3;
- each R6 is independently chosen from —NHR8, —NHC(NH)NHR8, and —CH2NHR8;
- R7a is cyano;
- each R7b is independently chosen from halo;
- each R8 is independently chosen from H and C1-3 alkyl;
- and
- R9 is chosen from cyano, C1-3 alkyl, C1-3 alkoxy, hydroxy, phosphonate, oxo, or any combination thereof,
- wherein if R5a is
- or optionally substituted by one or more R9, each R5b is H.
6-7. (canceled)
(canceled)
(canceled)
The compound of or a salt or tautomer thereof, wherein L2 is —C(O)—.
The compound of claim 51, or a salt or tautomer thereof, wherein R4 is 3-fluoro-4-cyanophenyl.
A compound of Formula I or II:
- or a salt or tautomer thereof, wherein:
- L1 is a bond;
- L2 is chosen from —C(O)NH—, —NHC(O)—, and —C(O)—;
- R1 is phenyl substituted with R5a;
- R2 is chosen from cyclohexyl, azetidinyl, pyrrolidinyl, and piperidinyl, any of which is optionally substituted with one or more R6;
- R4 is phenyl which is substituted with one R7a and optionally substituted with one or more R7b;
- R5a is OCH3;
- each R6 is independently chosen from —NHR8, —NHC(NH)NHR8, and —CH2NHR8;
- R7a is cyano;
- each R7b is independently chosen from halo;
- and
- each R8 is independently chosen from H and C1-3 alkyl.
A pharmaceutical composition comprising a compound as recited in ai, or a salt or tautomer thereof, together with a pharmaceutically acceptable carrier.
70-75. (canceled)
77-78. (canceled)
82-85. (canceled)
Dependencies are inferred from the claim text.